

In re application of:

RENNER et al.

Appl. No.: 10/050,902

Filed: January 18, 2002

For: Molecular Antigen Array

Confirmation No.: 7792

Art Unit: 1648

Examiner: Mosher, M.

Atty. Docket: 1700.0190004/BJD/SJE

## **Seventh Supplemental Information Disclosure Statement**

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Seventh Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Sixth Supplemental Information Disclosure Statement filed on October 29, 2003, in connection with the above-captioned application. A copy of each document is also provided.

A copy of document AB1 is not provided in accordance with the U.S. Patent and Trademark Office pre-OG notice of July 11, 2003, which states "[t]he Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003." Copies of the remaining documents are provided.

The Examiner is referred to the following related, co-pending patent application:

U.S. Patent Application No. 09/848,616, Pub. No. US 2003/0054010 A1, filed May 4, 2001, inventors Sebbel et al., cited herewith as Document AB1.

In accordance with the recent Federal Circuit decision in *Dayco Prods., Inc. v. Total Containment, Inc.* 329 F.3d 1358 (Fed. Cir. 2003), Applicants submit herewith Office Actions from the related copending U.S. Patent Application No. 09/848,616, as Documents AS133-AR134.

The identification of the listed U.S. Patent Application and the Office Actions is not to be construed as a waiver of secrecy as to this application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application, Office Actions and the art cited therein during examination of the present application.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Seventh Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$ 180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Brian Del Buono

Attorney for Applicants Registration No. 42,473

Date: July 21, 2004

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

256792\_1.DOC

•	PEVO	
	10 48	<b>—</b>
	7 10 m	Α.
	W2, E	1
FORM PTO-1449	1 705 72	F
		R
SEVENTH SUPPLEMEN	TARTENT , TO ACC	F
FORMATION DISCLOSURE S	STATEMENT	<u> </u>
	U.S. PAT	ΓE
		7

ATTY. DOCKET NO. 1700.0190004/BJD/SJE FIRST NAMED INVENTOR

APPLICATION NO. 10/050,902

ENNER et al.

FILING DATE
January 18, 2002

ART UNIT 1648

Page 1 of 4

MINER		DOCUME	ENT T		TENT DOCUMENTS	CLASS	SUB-CLASS	FILING DATE	
IAL		NUMBER		DATE	NAME	CLASS	SUB-CLASS	TIEMO DI II	
IAL	AA						1		
				00/00/0003	Sebbel et al.			05/04/2001	
	AB1	2003/00	54010 A1	03/20/2003	Sepper et al.				
	100								
	AC	•	ļ						
	AD	<del></del>				Ì			
	AE								
	AF	Ì							
	AG	<del>                                      </del>						ļ	
	1/10								
	AH								
	Al			}					
		<del> </del>							
	AJ								
	AK	+					ļ	ļ	
	1					NTC		<del></del>	
				FOREIGN	PATENT DOCUME	NIS			
AMINER			MENT	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATIC	
TIAL		NUMB	EK	DATE	00011111			`	
	AL							<del>                                     </del>	
								'	
	AM								
	AN							`	
	AO5	EDA	578 203 A1	01/12/1994	Europe				
	AOS	EFU	370 200 711	10171271001				Ţ·	
	AP5	wos	99/50432 A	10/07/1999	WIPO	1 2			
					thor, Title, Date, Per	tinent Pages, etc	fibroblostoid	myeloid and	
	AR	131	lymphoid B.V. (198	cells via transf 3)	fection or infection," G	ene 66.213-21 <del>9</del> ,	LISEVICI COIO		
	AS	131	Kilby, J.M., et al., "Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry," <i>Nat. Med. 4</i> :1302-1307, Nature America, Inc. (1998)						
	AT	131	McReyno Macmilla	McReynolds, L., et al., "Sequence of chicken ovalbumin mRNA," Nature 273:723-728, Macmillan Magazines, Ltd. (1978)					
						I DA	TE CONSIDERE	D	
						100	000.5		
XAMINEF	`				on is in conformance with N	ι			

Page 2 of 4

ATTY. DOCKET NO.

APPLICATION NO.

10/050,902

FORM PTO-1449

SEVENTH SUPPLEMENTAL

INFORMATION DISCLOSURE STATEMENTAL

INFORMATION DISCLOSURE STATEMENTAL

ART UNIT

January 18, 2002

1648

			U.S.	PATENT DOCUMENTS	3		·
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
_	AC						
	AD						
	AE						
	AF						
	AG						
<u> </u>	AH						
	Al						
	AJ						
	AK						
	<u> </u>		FOREI	GN PATENT DOCUME	NTS		
EXAMINER INITIAL		DOCUMEN	IT DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
		NUMBER					Yes No
	AL						Yes
	AM						No Yes
	AN					<del> </del>	No Yes
i	AO						No Yes
-	AP						No.
		OTI	IER (Including A	Author, Title, Date, Per the Editor: A Synthetic Pe	tinent Pages, etc	.) A1 Is a Potent li	nhibitor of Virus-
	AR	132 Wild, Medi	ated Cell-Cell Fusion	on," AIDS Res. Hum. Retro	oviruses 9:1051-105	3, Mary Ann Lie	bert, Inc. (1993)
	AS 132 Invitrogen Manual, "Sindbis Expression System Version C," from internet web page http://www.invitrogen.com/manuals.html, Catalog No. K750-01 (1996)						
	AT						
EXAMINER					•	CONSIDERE	
EXAMINER:	Initial if re	ference consider	ed, whether or not cita	ation is in conformance with M	IPEP 609. Draw line to	hrough citation if r	ot in conformance
and not consi	dered. Inc	dude copy of this	form with next comm	unication to Applicant.			

FORM PTO-1449

SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATUS ATTENDED TO THE PROPERTY OF THE PROPERTY OF

			U	.S. PATENT DOCUMEN	TS				
XAMINER NITIAL		DOCUMEN NUMBER		NAME	CLASS	SUB-CLASS	FILING DATE		
VIII/ (L.	AA								
	AB								
	AC								
	AD								
	AE								
	AF								
	AG								
	AH	-							
	Al								
	AJ								
	Al								
	<u> </u>		FO	REIGN PATENT DOCUM	MENTS				
EXAMINER INITIAL		DOCUM NUMBE		COUNTRY	CLASS	SUB-CLASS	TRANSLATION Yes		
	AL						No Yes		
	AM						No Yes		
	AN						No.		
	AO						No.		
	AP						Yes No		
			OTHER (Including	ng Author, Title, Date, F	Pertinent Pages, etc	2.) 1/00741 mailed l	March 5, 2002		
	AR	133	nemational Searci	1 Vebour for International Ve	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
		-   0	Office Action for related U.S. Application No. 08/848,616, mailed August 30, 2002						
	AS	133							
			Office Action for related U.S. Application No. 08/848,616, mailed February 7, 2003						
	АТ	133							
EXAMINER					DA	TE CONSIDERE	D		
EVAMINED:	Initial if re	eference cons	idered, whether or n	ot citation is in conformance wi	th MPEP 609. Draw line	through citation if	not in conformance		

	Page 4 o	f 4
ANY. DOCKET NO.	APPLICATION NO. 10/050,902	
FORM PTO-1449		
SEVENTH SUPPLEMENTAL FILES DATE	ART UNIT	
INFORMATION DISCLOSURE STATEMENT Jacainy 18, 2002	1040	_

			U.S.	PATENT DOCUMENTS	3		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
INTIAL	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG		-				
	AH						
<u> </u>	Al				i		
	AJ						
	Al	1					
				IGN PATENT DOCUME	NTS		
EXAMINER INITIAL		DOCUMEN NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION Yes
	AL						No Yes
	AM						No Yes
-	AN						No Yes
***	AO						No
	AP						Yes No
		OTH	IER (Including	Author, Title, Date, Per I U.S. Application No. 08/84	tinent Pages, etc	.)	
	AR	134	e Action for related	O.S. Application No. 06/64		Jei 31, 2000	
	AS						
	АТ						
EXAMINER					Į.	CONSIDERED	
EXAMINER:	Initial if re	ference considere	ed, whether or not cit	tation is in conformance with M nunication to Applicant.	IPEP 609. Draw line the	rough citation if n	ot in conformance
and not consid	Jereu. Inc	adde copy or this	TOTTI WILL HEAL COIL	normodilon to rippinodist			